Bioxytran (BIXT) Net Cash Flow (2010 - 2026)
Bioxytran (BIXT) posted Net Cash Flow of -$46867.0 for Q1 2026, down 109.46% sequentially from $495415.0 in Q4 2025, and down 5714.76% YoY from $834.71 in Q1 2025.
Bioxytran (BIXT) Net Cash Flow (2010 - 2026) Analysis & Trends
Bioxytran has reported Net Cash Flow for 17 years, with the latest figure at -$46867.0 in Q1 2026.
- Quarterly Net Cash Flow fell 5714.76% year-over-year to -$46867.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $458699.0 (up 8181.38% YoY) and the FY2025 annual result came in at $504760.0, up 2511.43% from the prior year.
- Net Cash Flow fell to -$46867.0 in Q1 2026 per BIXT's latest filing, from $495415.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $667226.0 in Q1 2022 and troughed at -$238907.0 in Q2 2022.
- A 5-year average of $22981.7 and a median of -$16062.0 in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2025 and 2026: Net Cash Flow surged 1778.35% in 2025, then slumped 5714.76% in 2026.
- Over 5 years, Net Cash Flow stood at -$78789.0 in 2022, then soared by 31.23% to -$54187.0 in 2023, then surged by 45.53% to -$29518.0 in 2024, then soared by 1778.35% to $495415.0 in 2025, then plunged by 109.46% to -$46867.0 in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$46867.0, $495415.0, and $11355.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | -285,663.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46,867.00 |
| Mar 31, 2026 | -46,867.00 |
| Dec 31, 2025 | 495,415.00 |
| Dec 31, 2025 | 495,415.00 |
| Sep 30, 2025 | 11,355.00 |
| Sep 30, 2025 | 11,355.00 |
| Jun 30, 2025 | -1,204.00 |
| Jun 30, 2025 | -1,204.00 |
| Mar 31, 2025 | -806.00 |
| Mar 31, 2025 | -806.00 |
| Dec 31, 2024 | -29,518.00 |
| Dec 31, 2024 | -29,518.00 |
| Sep 30, 2024 | 21,150.00 |
| Sep 30, 2024 | 21,150.00 |
| Jun 30, 2024 | 3,498.00 |
| Jun 30, 2024 | 3,498.00 |
| Mar 31, 2024 | -16,062.00 |
| Mar 31, 2024 | -16,062.00 |
| Dec 31, 2023 | -54,187.00 |
| Dec 31, 2023 | -54,187.00 |